Last updated on January 2019

Octaplas Pediatric Plasma Exchange Trial

Brief description of study

To assess the safety and tolerability of octaplas in the pediatric population by monitoring serious adverse drug reactions, adverse drug reactions (ADRs), thrombotic events (TEs), thromboembolic events (TEEs) and by measuring safety laboratory parameters.

Clinical Study Identifier: NCT01938378

Find a site near you

Start Over

Octapharma Research Site

Minneapolis, MN United States
  Connect »